In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Michael W. Magdycz
Advertisement
Articles by Michael W. Magdycz
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
2
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
3
Is FDA Streamlining Regulations in the Biosimilar Space?
4
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
5
